Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?

This review highlights that currently, monoclonal antibodies and other biological molecules are being approved at twice the rate of small therapeutic molecules. In order to assist financing, the article details some mechanisms that can be used to control drug prices.

British Journal of Clinical Pharmacology